• light
  • dark
holistic healing

The holistic health zone brings us together to support each other in our emotional, vibrational, heart, spirit, mind & soul healing.
group membership permissions:
open (public) group

who can see this group?
(show / hide) more from this group

share using

liking what we do here?

this site is advert free. your donations assist with keeping us online - click below to help us meet our technology costs


The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. - PubMed - NCBI

    ura soul
    The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.  - PubMed - NCBI

    cancer research paper showing that chemotherapy has a very low rate of success when the REAL and ABSOLUTE data is used to measure success rates, rather than the RELATIVE success rates used in 'marketing' from the cancer INDUSTRY.



    The debate on the funding and availability of cytotoxic drugs raises questions about the contribution of curative or adjuvant

    cytotoxic chemotherapy to survival in adult cancer patients.

    Materials and methods:

    We undertook a literature search for randomised clinical trials reporting a 5-year survival benefit attributable

    solely to cytotoxic chemotherapy in adult malignancies. The total number of newly diagnosed cancer patients for 22 major adult

    malignancies was determined from cancer registry data in Australia and from the Surveillance Epidemiology and End Results data in the

    USA for 1998. For each malignancy, the absolute number to benefit was the product of (a) the total number of persons with that

    malignancy; (b) the proportion or subgroup(s) of that malignancy showing a benefit; and (c) the percentage increase in 5-year survival due

    solely to cytotoxic chemotherapy. The overall contribution was the sum total of the absolute numbers showing a 5-year survival benefit

    expressed as a percentage of the total number for the 22 malignancies.


    The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in

    Australia and 2.1% in the USA.


    As the 5-year relative survival rate for cancer in Australia is now over 60%, it is clear that cytotoxic chemotherapy only makes

    a minor contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy,

    a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required